FCM
FUSN

Farallon Capital Management’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Farallon Capital Management’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-187,600
Closed -$2.25M – 153
2020
Q3 		$2.25M Sell
187,600
-62,400
-25% -$853K 0.02% 118
2020
Q2 		$4.37M Buy
+250,000
New +$4.35M 0.04% 111

Other funds holding FUSN

JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Farallon Capital Management's FUSN Position: Q4 2020 in Review

Farallon Capital Management sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q4 2020, closing a stake of 187,600 shares — an estimated $2.25M sold.

Farallon Capital Management first reported a position in FUSN in Q2 2020 and held it in 2 quarters. The position peaked at $4.37M in Q2 2020. 37 funds tracked by Wall St. Rank hold FUSN as of Q4 2020.

  • Farallon Capital Management reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q4 2020 after selling out during the quarter.
  • Farallon Capital Management sold 187,600 Fusion Pharmaceuticals Inc. Common Shares shares in Q4 2020, an estimated $2.25M.
  • Farallon Capital Management first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 2 quarters.
  • Farallon Capital Management's Fusion Pharmaceuticals Inc. Common Shares position peaked at $4.37M in Q2 2020.
  • 37 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q4 2020.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.